



Zelira Therapeutics Expands HOPE™ Distribution to Washington DC, USA

14 December 2020

- **Zelira enters into an exclusive licensing agreement with Alternative Solutions for HOPE™ products in the Washington DC Approved Medical Cannabis Market.**
- **Alternative Solutions will commercialize Zelira’s HOPE™ Products for sale in the second quarter of 2021.**
- **Zelira will receive a licensing fee and ongoing royalties on sales of HOPE™ within Washington DC**

Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the development of clinically validated cannabis medicines, is pleased to announce it has entered into a binding licensing agreement with Alternative Solutions LLC, a licensed grower, manufacturer and distributor of medical cannabis products in the District of Columbia (Washington DC) to manufacture and distribute Zelira’s HOPE™ products. Under the terms of the licensing agreement, Zelira will receive an upfront fee and ongoing royalties from HOPE™ product sales in Washington DC.

Washington DC has reciprocity with 32 other states in the USA with approved medical cannabis programs. This expands access to patients registered in all the 32 states as they can legally purchase medical cannabis products at an approved dispensary in Washington DC.

Zelira previously licensed HOPE™ in Pennsylvania to Ilera Healthcare LLC which holds the license for that State and in Louisiana to Advanced Biomedics LLC. Zelira remains focussed on expanding the distribution of HOPE™ through licensing agreements in each approved market across the USA next year, as the COVID-19 pandemic gets under control.

Dr Oludare Odumosu, CEO & Managing Director USA for Zelira said “Our partnership with Alternative Solution, a leader in the Washington DC market, is a strategic move in line with our mission of working with market leaders in approved markets to expand access to HOPE™ across the USA. We are particularly excited about this partnership because Washington DC is a gateway state with over 24 million visitors passing through the US capital in a year. Washington DC’s reciprocity is a strategic move that allows approved patients from 32 states to legally access HOPE™ in DC.”

Matt Lawson-Baker, CEO for Alternative Solutions said “Alternative Solutions is thrilled to be partnering with Zelira to bring the HOPE™ product line to the Washington DC medical cannabis market. Providing

access to this medicine in the Nation’s capital will give many families and patients the treatment they deserve through a legal regulated medical cannabis program.”

DISCLOSURES:

This announcement has been approved and authorised for release by the board of Zelira Therapeutics Limited.

Oludare Odumosu

Managing Director USA

About Zelira Therapeutics (www.zeliratx.com)

Zelira Therapeutics Ltd is a leading global therapeutic medical cannabis company with access to the world’s largest and fastest growing cannabis markets. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets from 2020. The company is focused on developing branded cannabis products for the treatment of a variety of medical conditions.

The Company is undertaking product development programs targeting specific conditions and human clinical trial programs focused on insomnia, autism and opioid reduction in patients with chronic non-cancer pain.

The Company has developed two proprietary formulations (HOPE™) targeting Autism Spectrum Disorder already launched and generating revenues in Pennsylvania and Louisiana and Australia. Zelira has also launched Zenivol™ in Australia as the worlds leading clinically validated proprietary formulation for treatment of chronic insomnia.

The Company conducts this work in partnership with world-leading researchers and organizations including Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent’s Hospital in Melbourne, Australia; and the Children’s Hospital of Philadelphia (CHOP) in the United States.

About Alternative Solutions (www.altsol.co)

Montana Apocathary d/b/a Alternative Solutions is one of eight current license holders for the cultivation, processing and distribution of cannabis within the District of Columbia. Alternative Solutions is licensed to distribute medical cannabis products to all seven licensed MMJ dispensaries within the District. Operational since 2015, Alternative Solutions focuses on providing a consistent supply of premium products to all licensed dispensaries in DC.

Address

Level 26
140 St Georges Terrace
Perth WA 6000
AUSTRALIA
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeliratx.com
W: www.zeliratx.com
ACN 103 782 378

Australia Contacts:

Dr. Richard Hopkins
Managing Director & CEO, Ex USA
+61 405 656 868
rhopkins@zeliratx.com
Level 26, 140 St Georges Terrace
Perth WA 6000
AUSTRALIA

U.S. Contacts:

Dr. Oludare Odumosu
Managing Director & CEO, USA
+1 909 855 0675
oodumosu@zeliratx.com
3553 West Chester Pike #110
Newtown Square PA 19073
UNITED STATES OF AMERICA

Tickers

Australia (ASX): ZLD
USA (OTCQB): ZLDAF

Monsoon Communications

Rudi Michelson
+61 3 9620 3333
rudim@monsoon.com

GVM Communications, Inc.

Gia Morón
+1 347 678 8079
gia@gvmcommsinc.com